The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

The Rationale Behind CheckMate-275 in Metastatic Bladder Cancer

Matthew Galsky, MD
Published Online: 7:07 PM, Tue October 11, 2016


Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress. The trial assessed the activity and safety of nivolumab (Opdivo) in patients with metastatic bladder cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.